Traditional in vitro drug discovery methods often fail to accurately replicate the complex physiology of the human body, leading to inaccurate predictions of drug efficacy and toxicity. Reliance on animal testing increases costs and timelines, while also raising ethical concerns and potentially failing to translate to human outcomes.

FluoSphera offers a chip-free, high-throughput 3D cell culture platform designed to mimic human physiology for improved in vitro drug discovery. The platform enables researchers to study the human response to systemic drug delivery with greater precision and speed. By recapitulating human first-pass liver Drug Metabolism and PharmacoKinetics (DMPK), the system allows for early detection of systemic drug effects typically observed only in animal models or patients. This approach facilitates rapid evaluation of drug efficacy and toxicity, reduces the need for animal testing, and optimizes pre-clinical testing strategies. The modular technology allows for individual project customization and the ability to evaluate over 1000 compounds with 28 simultaneous readouts.

Chip-free 3D cell culture technology that mimics the natural physiology of the human body.

High-throughput screening capabilities for rapid evaluation of drug candidates.

Systemic exposure module that recapitulates human first-pass liver Drug Metabolism and PharmacoKinetics (DMPK).

Multiplexing technology allowing for >1000 compounds to be evaluated with 28 simultaneous readouts.

Modular technology allowing for individual project customization.

The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.